The Patent Finder

Novimmune S.A.

41 patents currently held · Updated Nov 16, 2026
10 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 4 name spellings.

12
Ending by 2030
Aug 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Mar 3 to 24, 2027 · next Mar 3
  • 1 fee due Apr 29, 2027
    The maintenance fee for Methods of Purifying Bispecific Antibodies (US 10,457,749) comes due Apr 29, 2027. Unpaid by Oct 29, 2027, it lapses early.
  • 2 fees due Jun 3 to 12, 2027 · next Jun 3
  • 1 fee due Jul 12, 2027
    The maintenance fee for Methods of treating autoimmune diseases using anti-IL6/IL-6R complex antibodies (US 9,234,034) comes due Jul 12, 2027. Unpaid by Jan 12, 2028, it lapses early.
  • 1 fee due Aug 11, 2027
    The maintenance fee for Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers (US 10,556,960) comes due Aug 11, 2027. Unpaid by Feb 11, 2028, it lapses early.
  • 1 fee due Sep 24, 2027
    The maintenance fee for Methods for the generation of multispecific and multivalent antibodies (US 10,597,465) comes due Sep 24, 2027. Unpaid by Mar 24, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 18, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 9,850,304Anti-CD3 antibodies and methods of use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,728,114Anti-CD3 antibodies and methods of use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,110,661Anti-IP-10 antibodies and methods of use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,258,267Human anti-IP-10 antibodies uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 7,786,268Anti-IP-10 antibodies and methods of use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,337,849ANTI-IL6/IL-6R Antibodies and Methods of Use Thereof
In force
 · Medium confidence
In forceMedium confidence
US 9,234,034Methods of treating autoimmune diseases using anti-IL6/IL-6R complex antibodies
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,828,430Anti-IL-6/IL-6R antibodies
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,759,862Anti-IL-6/IL-6R antibodies and methods of use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,688,755Fc receptor-binding polypeptides with modified effector functions
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 41 patents shown.
Pro members see all 41.
Pro members: see all 41 patents
Also on record, not counted in the 41: 10 patents in force now held by others · 9 lapsed for an unpaid fee · 17 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

6 pending · 5 abandoned · 21 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited